In another Phase III study called CLEOPATRA, 808 women with HER2-positive advanced breast cancer were enrolled, and the efficacy of pertuzumab combined with trastuzumab and docetaxel was compared to trastuzumab combined with docetaxel as the first-line treatment. This evidence concerns the gene ERBB2 and breast cancer.